Lupin Pharmaceuticals

What Lupin Pharmaceuticals does

Lupin Pharmaceuticals, Inc. (LPI) is the U.S. commercial subsidiary of Lupin Ltd, the Indian multinational pharmaceutical company founded in 1968 by Dr. Desh Bandhu Gupta. Headquartered in Naples, Florida, LPI commercializes a diversified pharmaceutical portfolio spanning generics, complex generics, inhalation medications, branded products, and specialty medicines, serving healthcare providers and patients across 100+ countries. The company is a major pharmaceutical player by prescriptions in the U.S. and operates through country-specific brand entities in Canada, the UK, Germany, Australia, Brazil, Mexico, South Africa, the Philippines, Switzerland, and the Netherlands.

The company's underlying technology platform centers on advanced pharmaceutical manufacturing, including a proprietary long-acting injectable platform branded PrecisionSphere™, from which Lupin launched Risperidone Long-Acting Injectable with 180-day Competitive Generic Therapy exclusivity in the U.S. in November 2025. Additional capability is being built in peptide ingredient production and contract development and manufacturing services (CDMO) through an expansion of the Dabhasa, India facility, targeting the global advanced therapeutics and peptide market. The company also offers generics and complex generics across multiple therapeutic areas and an innovative medicines portfolio addressing unmet medical needs.

Lupin's revenue model is built on traditional pharmaceutical distribution: products move through wholesale distributors, pharmacy networks, healthcare institutions, and institutional buyers in the U.S. and global markets. Pricing is not publicly disclosed at the product level. Recent significant cash outflows include a $90 million settlement with Astellas over Mirabegron patent litigation and a $30 million antitrust settlement with Humana as part of the consolidated In Re Generic Pharmaceuticals Antitrust Litigation. Marketing channels are primarily LinkedIn and the corporate news/media section, with no public pricing or digital channel data disclosed.

Name

Lupin Pharmaceuticals

Legal name

Lupin Pharmaceuticals, Inc.

Website

https://lupinpharmaceuticals.com

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Lupin Pharmaceuticals, Inc. is the U.S. commercial subsidiary of Indian parent Lupin Ltd, commercializing generics, complex generics, inhalation, branded, and specialty medicines across 100+ countries via its proprietary PrecisionSphere™ injectable platform and traditional pharmaceutical distribution channels.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Generic pharmaceuticals
• Complex generic drugs
• Pharmaceutical manufacturing
• Specialty medications
• Inhalation drug delivery

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Core offering

Lupin Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and commercializes generic, complex generic, inhalation, branded, and specialty pharmaceutical products for the U.S. and international markets. The company also operates proprietary drug delivery platforms such as PrecisionSphere™ for long-acting injectables and provides contract development and manufacturing (CDMO) services for peptides and advanced therapeutics.

Product overview

Lupin Pharmaceuticals is a global pharmaceutical company offering a diversified portfolio of generic medicines, complex generics, innovative medicines, and specialty medications. The company operates its proprietary PrecisionSphere™ long-acting injectable platform for extended-release formulations. Product offerings include generics and complex generics targeting various therapeutic areas, innovative branded medications, and contract development manufacturing (CDMO) services for peptides and advanced therapeutics through its expanded Dabhasa facility in India.

Differentiator

Problem solved

Functional benefit

Products and services

• Risperidone Long-Acting Injectable A long-acting injectable formulation of risperidone, used in the treatment of psychiatric conditions such as schizophrenia and bipolar disorder, offered to U.S. healthcare providers and patients with 180-day competitive generic therapy exclusivity.
• Generics and Complex Generics Lupin's core portfolio of generic pharmaceutical products, including complex generics that provide cost-effective alternatives to brand-name medications across a broad range of therapeutic areas, targeting patients and healthcare providers globally.
• Innovative Medicines (Branded and Specialty) Specialty and branded pharmaceutical products focused on addressing unmet medical needs through novel therapeutic approaches, including inhalation medications, for healthcare providers and patients.
• Mirabegron Generic Generic version of Astellas' Myrbetriq (mirabegron), a medication used for the treatment of overactive bladder, offered as a cost-effective alternative to the brand-name product for U.S. patients and healthcare providers.
• Peptide CDMO Services Contract development and manufacturing services for peptides and advanced therapeutics, supported by Lupin's expanded Dabhasa facility in India with peptide ingredient production capacity, offered to pharmaceutical and biotechnology clients in the global peptide market.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Teva Pharmaceutical Industries: Largest generic pharmaceutical manufacturer globally with a deep US generics portfolio. Directly comparable to Lupin in oral solids, complex generics, and specialty categories, with overlapping therapeutic areas.
• Sandoz (Novartis): Pure-play global generics and biosimilars leader spun out of Novartis. Directly competes with Lupin in US retail generics and complex generics, with similar customer bases (pharmacies, wholesalers, hospitals).
• Viatris: Major US-headquartered generics and specialty pharma company formed via Mylan-Upjohn merger. Direct competitor in generic and complex generics across the same channels as Lupin.
• Apotex: Canadian-based generic pharmaceutical manufacturer with significant US market presence. Directly comparable to Lupin in oral solid generics, complex generics, and injectable product lines.
• Aurobindo Pharma: India-based global generic pharmaceutical company with a substantial US subsidiary (Aurobindo Pharma USA). Closely comparable Indian-headquartered peer with overlapping US generics portfolio and similar scale.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company and major US generics player via Sun Pharma Global FZE. Directly comparable Indian peer with similar specialty-generics mix and US distribution footprint.
• Dr. Reddy's Laboratories: Indian multinational generic and specialty pharmaceutical company with strong US operations. Directly comparable to Lupin in injectable generics, biosimilars, and branded specialty categories.
• Hikma Pharmaceuticals: Jordan-headquartered specialty and generic pharmaceutical company with major US operations (Hikma Pharmaceuticals USA). Comparable to Lupin in injectables, generics, and specialty branded products.
• Zydus Lifesciences: Indian multinational pharmaceutical company with US generics operations. Comparable Indian-headquartered peer with similar strategic focus on complex generics and specialty products in the US market.

Broad incumbents

• Endo International: US-focused specialty pharmaceutical company with generics and branded specialty franchises. Overlaps with Lupin's specialty generics portfolio and serves similar physician/payer customers in the US market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lupin-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lupin Pharmaceuticals